NEW YORK (Reuters) – Bristol-Myers Squibb Co is confident it will receive U.S. approvals for all three experimental drugs tied to a potentially higher payout for Celgene shareholders under terms of its acquisition of the U.S. biotech company, Bristol’s chief medical officer said. FILE PHOTO: Logo of global biopharmaceutical company Bristol-Myers Squibb is pictured on the blouse of an employee in Le Passage, near Agen, France March 29, 2018. REUTERS/Regis Duvignau/File Photo New York-based Bristol-Myers bought Celgene for more than $74 billion in a deal announced last January. As part of that agreement, Celgene shareholders received a so-called CVR, or contingent value right, worth $9 per share if three high-profile drugs in Celgene’s pipeline receive U.S. approvals by March 2021. “We don’t see why we would not be on track for that,” Bristol-Myers CMO Samit Hirawat said in an interview when asked the prospects for achieving that goal. The CVR BMY_r.N closed on Wednesday at $3.41 per unit, implying that investors currently give the company a roughly 40% chance of succeeding. That will depend on the U.S. Food and Drug Administration, which must still review and approve all three drugs. The first of the three medicines included in the CVR…